title: Tidal breathing flow-volume loops in bronchiolitis in infancy: the effect of albuterol [ISRCTN47364493].
abstract: OBJECTIVE
  To evaluate the effect of nebulized albuterol on tidal breathing flow-volume loops in infants with bronchiolitis due to respiratory syncytial virus.
  
  
  METHODS
  A randomized, double-blind, control study.
  
  
  METHODS
  Pediatric unit in a community teaching hospital.
  
  
  METHODS
  Twenty infants younger than 1 year of age (mean age, 5.8 +/- 2.8 months) with a first episode of wheezing due to respiratory syncytial virus bronchiolitis.
  
  
  METHODS
  Chloral hydrate (50 mg/kg) was administered orally for sedation. One dose each of nebulized albuterol (0.15 mg/kg in 3 ml saline) and saline (3 ml) were given at 6 hour intervals in a random order.
  
  
  METHODS
  Tidal breathing flow-volume loops were obtained before and after each aerosol treatment with a Neonatal/Pediatric Pulmonary Testing System (Model 2600; Sensor Medics, Anaheim, CA, USA). At the same time, the fraction of tidal volume exhaled at peak tidal expiratory flow (PTEF) to total tidal volume (VPTEF/VE), and the fraction of exhaled time at PTEF to total expiratory time (tPTEF/tE) were measured. The PTEF, the tidal expiratory flows at 10%, 25%, and 50% of the remaining tidal volume (TEF10, TEF25, and TEF50), and the wheeze score were also determined.
  
  
  RESULTS
  There were no significant changes in VPTEF/VE and tPTEF/tE after albuterol or saline treatment. PTEF increased significantly both after albuterol and saline treatments but the difference between the two treatments was not significant (P = 0.6). Both TEF10 and the ratio of the tidal expiratory flow at 25% of the remaining tidal volume to PTEF (25/PT) decreased significantly (P < 0.05) after administration of albuterol. All other investigated variables were not significantly affected by aerosol administration.
  
  
  CONCLUSIONS
  Nebulized albuterol in infants with mild bronchiolitis due to respiratory syncytial virus did not improve VPTEF/VE and tPTEF/tE but did decrease TEF10 and 25/PT.
authors: Division of Critical Care Medicine, Miami Children's Hospital, Florida, USA. bala.totapally@mch.com
authors: Balagangadhar R
authors: BR
authors: Totapally
authors: Cem
authors: C
authors: Demerci
authors: George
authors: G
authors: Zureikat
authors: Brian
authors: B
authors: Nolan
mesh_terms: D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001988:Bronchiolitis / Q000188:drug therapy* / Q000821:virology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009330:Nebulizers and Vaporizers; D012129:Respiratory Function Tests; D012136:Respiratory Syncytial Viruses / Q000302:isolation & purification*; D013990:Tidal Volume / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol